Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Azelon completes clinical trial to compare nasal spray ZT-034 to Forteo
Patients in the phase 2 study, which saw the enrollment of 130 women with low bone mass in multiple centers across the US, received one of three treatments:
Patients in the phase 2 study, which saw the enrollment of 130 women with low bone mass in multiple centers across the US, received one of three treatments:
Ficlatuzumab is a humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met
Janssen said the drug is used to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent symptomatic venous thromboembolism (VTE). The company
Financial details for the research partnership have not been disclosed. As part of the research partnership, both companies will focus on screening for biased ligands against an undisclosed
The mobile cloud-based solution will eliminate servers, forgo the need of internal staff constantly upgrading software and improving the customers’ experience. Using MaaS360’s secure document sharing feature, the
Lorus has discovered IL-17E (also known as IL-25) cytokine that plays a vital role in inflammation and has potent anticancer properties. Lorus president and CEO Aiping Young said
The Study 116, a randomized, double-blind study, will enroll 160 patients to evaluate the utility of GS-1101 in combination with various chemoimmunotherapies in previously treated CLL patients. The
The two patents, owned by Aptalis and licensed to Cephalon, will expire in 2023 and 2025. Aptalis president John Fraher said, "Aptalis Pharmaceutical Technologies endeavors to offer to
The UPS 4 blister line provides primary packaging into a series of materials including PVC, PVC/PVDC, Aclar and Alu/Alu, by processing solid oral dose products. Almac manufacturing operations
The patent covers Inovio’s synthetic consensus HPV antigens, DNA constructs and vaccines that include these antigens, including VGX-3100, cervical dysplasia/cancer vaccine. The methods used for treating patients with